Andrew Mardis retweeted
“After more than 40 years together, I know when ‘I’m fine’ doesn’t necessarily mean he’s fine.” Liz on being a care partner to her husband Art, who lives with hereditary ATTR. Learn more about Liz's story she shared with us for #CaregiverAwarenessMonth: bit.ly/4sQP49Z
Andrew Mardis retweeted
For Gesna, her ATTR-CM diagnosis brought clarity to the symptoms that had impacted her family for generations.
This #AmyloidosisAwarenessMonth, she's sharing her experience to encourage earlier conversations around family health history and greater awareness of hereditary ATTR (#ATTRv), especially in the African American community, where certain genetic variants may be more prevalent but remain underrecognized.
By sharing her story, Gesna hopes to empower more people to ask questions, understand their risk, and take proactive steps toward earlier testing and care.
Andrew Mardis retweeted
1/43 Welcome to this MedX CME on transthyretin amyloid cardiomyopathy (ATTR-CM), including updates in treatment from ACC25, with cardiologist Michelle Kittleson, MD, PhD.
Earn credit: link.med-iq.com/57jSxO
Andrew Mardis retweeted
Excited to announce the dosing of our first participant in ACT-EARLY, the first-ever primary prevention study for ATTR testing if prophylactic treatment of asymptomatic carriers with acoramidis can delay or prevent disease onset. Learn more: bit.ly/4jPqdhn
Andrew Mardis retweeted
In the April #BPS Leadership Blog, Andrew Mardis, Medical Science Liaison, highlights the value of board certification throughout his career, even as he transitioned away from direct patient care.
Read his blog here: bpsweb.org/2025/04/28/mainta…
Andrew Mardis retweeted
This year at @ACCintouch, we met with leaders in cardiology and learned about innovative developments for patients with heart conditions like ATTR-CM. We also had the opportunity to share findings from ATTRibute-CM, our Phase 3 clinical trial for ATTR-CM. #ACC25
Andrew Mardis retweeted
Join us this year at @ACCintouch 2025 in Chicago! We’ll be providing new updates on our TTR stabilizer for ATTR-CM as well as supporting an industry expert theater with @Medscape. Learn more: investor.bridgebio.com/press… #ACC25
Andrew Mardis retweeted
We’re excited to announce that data from the ATTRibute-CM Phase 3 study will be presented at the @ACCinTouch 2025. The data on cardiovascular outcomes in variant and wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) patients will be featured in a flat board poster presentation. We will also share five posters and two moderated posters on ATTR-CM. Learn more: bit.ly/4kTBP3Y #ACC2025
Andrew Mardis retweeted
📢 Fellowship Opportunity! Apply Now!
🏥 The Medical University of South Carolina’s Division of Cardiology is now accepting applications for a one-year, non-ACGME Amyloidosis Fellowship.
🔬 Gain specialized clinical & research training in amyloidosis and advance your expertise!
Andrew Mardis retweeted
🚨 Early diagnosis = better outcomes! Learn to spot clinical signs of ATTR-CM, use biomarkers for precision care, and implement evidence-based management strategies. 🏥 #ACC25
🔗 Secure your spot now: ms.spr.ly/6013qEVtv
@SarswatNitasha
Andrew Mardis retweeted
It is #AmyloidosisAwarenessMonth
#DYK ATTR can impact individuals at any age? Follow along this month as we work to #IlluminateATTR, today and all year long.
Andrew Mardis retweeted
ASNC Masterclass: Cardiac Amyloidosis
Join Dr. Frederick Ruberg & Dr. Andrew Staron of @BU_Amyloidosis for an expert-led session on the latest in cardiac amyloidosis imaging & management!
Learn from top experts in the field!#ASNC
📅 March 7-9, 2025
💻 Virtual Event – Open to All!
Andrew Mardis retweeted
Cooper Manning shares his approach to parenting Arch in the era of NIL and the evolving landscape of college football.
Andrew Mardis retweeted
Happening 12/3! HFSA Education Partner Program: Don't Fail Them Now: Bridging Diagnostic and Treatment Gaps in Transthyretin Cardiac Amyloidosis. Discover More >> bit.ly/3Z7JAtc
Andrew Mardis retweeted
Join us at #AHA24! We’ll be presenting a featured science presentation on our outcomes data through 42 months from the open-label extension of ATTRibute-CM, our Phase 3 Study of acoramidis for ATTR-CM & three moderated digital poster presentations. bit.ly/4eYVDPW
Andrew Mardis retweeted
In honor of World Amyloidosis Day, we hope to raise awareness about how people are impacted by amyloidosis. We believe that by providing education about the condition, we will help eliminate delays in diagnostics for patients. Learn about how to support the amyloidosis community: bit.ly/3PPUvnX #WorldAmyloidosisDay
Andrew Mardis retweeted
🚀 Elevate your expertise in ATTR-CM at the 3rd International Congress on ATTR Amyloidosis. Interactive, 🧠 expert-led session with @maz_hanna, @BrettSperryMD, @NotNoninvasive and @Ron_Witteles.
Click here now: ms.spr.ly/6013mmT3B
#ICAAlive24
Andrew Mardis retweeted
We’re thrilled to share our outcomes data from our long-term open-label extension of ATTRibute-CM, our Phase 3 study of acoramidis in ATTR-CM, in a featured science oral presentation at the 2024 @American_Heart Scientific Sessions. Learn more: bit.ly/4eNw9V8



























